Outdated Information and Misinformation: Many healthcare providers, while well-intentioned, are operating with a simplified or outdated understanding of B12 metabolism and the needs of Pernicious Anemia patients
In one single-center trial of 72 subjects using a controlled-adverse-environment model, the T4 eye drop did not meet its co-primary endpoints (ocular discomfort and inferior corneal staining) at the primary time point, but it did produce statistically significant improvements on several secondary endpoints, including central and superior corneal staining, with no adverse events reported
intravenous TB-4 Phase 1 safety and pharmacokinetics, no dose-limiting or serious adverse events (Ann N Y Acad Sci 2010;1194:223229): NCT00743769 On February 27, 2026, HHS Secretary Kennedy announced that GHK-Cu is among approximately 14 peptides expected to return to Category 1
Vague codes like "unspecified" invite payer review
Ensure staff check and document BUDs at each administration and follow your SOPs
